CSL paying $312m to license mRNA vax tech

November 02, 2022 10:45 AM AEDT | By AAPNEWS

Google News:

Image source: AAPNEWS

Recent News

Lynas (ASX:LYC) Boosts Rare Earth Capabilities with First Terbium Oxid...

Boss Energy Hits Production Milestone at Honeymoon Mine, Solidifying P...

Karoon Energy Expands Footprint in Santos Basin with New Exploration B...

ASX200 Opens Lower as Iron Ore Dips; Energy and Uranium Stocks Buck th...

CSL says it is paying $US200 million ($A312m) up-front to license next-generation mRNA vaccine technology from a small US company.

CSL said on Wednesday its CSL Seqirus subsidiary, the second-biggest flu vaccine manufacturer globally, has licensed the technology from NASDAQ-listed Arcturus Therapeutics.

The $US485m NASDAQ-listed company would be eligible to receive more than $US4.3 billion ($A6.7 billion) in milestone payments, plus double-digit royalties under the terms of the deal.

Arcturus has been working on a COVID-19 vaccine, which a large-scale clinical trial in April found was safe and effective, that might be used as a booster shot, as well as mRNA-based vaccines for flu and other respiratory diseases.

Arcturus' mRNA vaccines use "self-amplifying" technology, meaning the vaccines are programmed to make more copies of themselves within the body, so a much smaller dose is needed than with the mRNA vaccines made by Pfizer and Moderna.

CSL is working on its own flu vaccine using self-amplifying mRNA but has only progressed as far as mice studies, which have been promising.

"This collaboration is an exciting opportunity to complement CSL's own next generation mRNA program with a partner who developed a platform to deliver late stage clinical supplies at scale," said CSL chief operating officer Paul McKenzie.

"These combined capabilities will accelerate our journey in mRNA."

CSL chief medical officer Dr Bill Mezzanotte called the deal "another example of CSL's relentless pursuit of disruptive innovation when public health and patients can benefit."

San Diego-based Arcturus Therapeutics was founded in 2013 and has around 200 employees.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.